Krystal Biotech, Inc. Earnings Recaps
Shares fell 11.0% after earnings, with the clearest concern being delayed timing for some clinical readouts: management said results are now expected in the upcoming months, later than hoped. That pipeline uncertainty weighed against continued commercial growth and profitability.
Key takeaways
- VYJUVEK revenue was $127.3 million, up 30% year over year; international revenue was $32 million and U.S. net revenue was $95.3 million.
- The company reported diluted EPS of $2.05 and ended September with $1.2 billion in cash and investments.
- Management updated timing for some clinical readouts, saying results are expected in the upcoming months; it did not provide specific dates on this call.
- International access progressed: pricing negotiations concluded in Italy, with launch expected in early 2027; Spain pricing discussions are ongoing, with a decision expected before year-end.
- The board authorized a share repurchase program of up to $400 million, expected to be deployed over the next two years.
Krystal Biotech’s shares fell 4.8% following the quarter, driven primarily by a disappointing outlook on pricing and reimbursement progress in Europe leading to a revenue reserve in Germany. Despite operational momentum, investor concerns over continued market access hurdles and muted near-term revenue growth weighed on sentiment.
Key takeaways
- Europe and Japan revenues remained broadly flat in Q2, impacted by a reserve provision related to uncertain pricing outcomes in Germany.
- Ongoing reimbursement negotiations in key EU markets like Germany, Italy, and Spain are delaying sustained revenue growth, with formal pricing decisions expected to continue through 2026 and 2027.
- U.S. net revenue was $91.6 million, reflecting steady commercial traction and expansion into community settings.
- International launches show growth in patient and treatment volumes but face operational challenges, including fragmented care centers in Germany and access restrictions in France and Japan.
- Multiple upcoming regulatory submissions in other countries are planned, but market access remains a significant near-term obstacle to revenue scaling.
Krystal Biotech delivered a strong Q3 2025, with VYJUVEK revenues reaching $97.8 million, bolstered by recent expansions in Europe and Japan. The company is well-positioned for sustained growth with an expanding prescriber base and new clinical programs underway.
Key takeaways
- VYJUVEK revenues total $97.8 million for Q3, contributing to over $623 million since the product’s launch.
- Gross margins remained robust at 96%, with an acceleration in over 40 new reimbursement approvals in the U.S. since the last earnings call.
- Successful launches of VYJUVEK in Germany, France, and Japan are set to enhance patient access and treatment availability.
- The updated U.S. label for VYJUVEK now includes patients from birth, optimizing the product's market position and potential for higher compliance.
- Initiation of a new clinical program for Hailey-Hailey disease reinforces Krystal’s commitment to rare disease treatments and expands their innovative pipeline.